Retatrutide Peptide is an advanced synthetic tri-agonist researched for its interaction with GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors in experimental metabolic studies. It is currently under investigation for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD).
Structurally engineered for enhanced stability and multi-receptor engagement, Retatrutide Peptide is widely utilized in preclinical research to study receptor binding kinetics, cAMP-mediated intracellular signaling pathways, metabolic regulation, and coordinated endocrine responses under controlled laboratory conditions.
Its innovative triple-receptor mechanism has positioned Retatrutide as a significant focus in modern metabolic and peptide research applications.
